GIP stands for glucose-dependent insulinotropic polypeptide, another hormone released in the gut when we eat
[1] [2] Ozempic improves glycaemic control in adults with type 2 diabetes, and while cardiovascular outcomes benefits were observed in clinical trials (SUSTAIN-6), this is not a separate licensed indication in the UK
Work closely with your healthcare provider to establish a personalized timeline based on your health history

GLP-3 Lets break down the key differences in a clear, comparative format: Primary Location of Action GLP-1: Pancreas, brain, stomach, cardiovascular system GLP-2: Intestinal tract, gut epithelium GLP-3: Unknown/under investigation Main Functions GLP-1: Regulates blood sugar Suppresses appetite Promotes weight loss Slows gastric emptying Protects cardiovascular system GLP-2: Promotes intestinal growth Enhances nutrient absorption Repairs gut lining Reduces inflammation Strengthens gut barrier GLP-3: Functions not well established Potentially metabolic or intestinal Requires more research Clinical Applications GLP-1: Type 2 diabetes treatment Obesity and weight management Cardiovascular disease prevention Potential neuroprotection GLP-2: Short bowel syndrome Inflammatory bowel disease (experimental) Intestinal injury recovery Malabsorption disorders GLP-3: No established clinical applications Currently research-only Half-Life GLP-1: Very short (2 minutes for natural form

Los adultos con diabetes tipo 2, un ndice de masa corporal (IMC) de 30 o ms, o un IMC de 27 o ms con complicaciones relacionadas con la salud, como presin arterial alta y apnea del sueo, podran considerar el tratamiento con un medicamento GLP-1